| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Biological feasibility and importance of a gonorrhea vaccine for global public health
|
Vincent, Leah R.
|
|
|
37 |
50 |
p. 7419-7426
|
article
|
| 2 |
Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development
|
Schiffer, Joshua T.
|
|
|
37 |
50 |
p. 7363-7371
|
article
|
| 3 |
Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy
|
Hosangadi, Divya
|
|
|
37 |
50 |
p. 7372-7380
|
article
|
| 4 |
Defining a correlate of protection for chikungunya virus vaccines
|
Milligan, Gregg N.
|
|
|
37 |
50 |
p. 7427-7436
|
article
|
| 5 |
Editorial Board/Aims and Scope
|
|
|
|
37 |
50 |
p. IFC
|
article
|
| 6 |
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics
|
Vekemans, Johan
|
|
|
37 |
50 |
p. 7391-7393
|
article
|
| 7 |
Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017
|
Gottlieb, Sami L.
|
|
|
37 |
50 |
p. 7408-7418
|
article
|
| 8 |
Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency
|
Vannice, K.S.
|
|
|
37 |
50 |
p. 7443-7450
|
article
|
| 9 |
Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25–26 April 2016
|
Giersing, Birgitte K.
|
|
|
37 |
50 |
p. 7355-7362
|
article
|
| 10 |
Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling
|
Gottlieb, Sami L.
|
|
|
37 |
50 |
p. 7336-7345
|
article
|
| 11 |
National Institute of Allergy and Infectious Diseases workshop report: “Chlamydia vaccines: The way forward”
|
Zhong, Guangming
|
|
|
37 |
50 |
p. 7346-7354
|
article
|
| 12 |
Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016
|
Giersing, Birgitte K.
|
|
|
37 |
50 |
p. 7315-7327
|
article
|
| 13 |
Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics
|
Vekemans, Johan
|
|
|
37 |
50 |
p. 7394-7395
|
article
|
| 14 |
Review of mathematical models of HSV-2 vaccination: Implications for vaccine development
|
Spicknall, Ian H.
|
|
|
37 |
50 |
p. 7396-7407
|
article
|
| 15 |
Status of vaccine research and development for Clostridium difficile
|
Riley, T.V.
|
|
|
37 |
50 |
p. 7300-7306
|
article
|
| 16 |
Status of vaccine research and development for Helicobacter pylori
|
Sutton, Philip
|
|
|
37 |
50 |
p. 7295-7299
|
article
|
| 17 |
Status of vaccine research and development of vaccines for Chlamydia trachomatis infection
|
Poston, Taylor B.
|
|
|
37 |
50 |
p. 7289-7294
|
article
|
| 18 |
The rotavirus vaccine development pipeline
|
Kirkwood, Carl D.
|
|
|
37 |
50 |
p. 7328-7335
|
article
|
| 19 |
Vaccination against the human cytomegalovirus
|
Plotkin, Stanley A.
|
|
|
37 |
50 |
p. 7437-7442
|
article
|
| 20 |
WHO consultation on ETEC and Shigella burden of disease, Geneva, 6–7th April 2017: Meeting report
|
Hosangadi, Divya
|
|
|
37 |
50 |
p. 7381-7390
|
article
|
| 21 |
WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016
|
Kobayashi, Miwako
|
|
|
37 |
50 |
p. 7307-7314
|
article
|
Journal description